What this pack is
DETROL LA is the brand name in this record; tolterodine tartrate extended-release capsules is the generic name. Read both together with the dosage form (oral capsule).
PACK CHECK · MARKET FIRST
DETROL LAGeneric nametolterodine tartrate extended-release capsules
How this medicine works
Tolterodine and its active metabolite act through muscarinic-receptor pathways related to bladder contraction, while the extended-release capsule describes how medicine is released. Mechanism explains product design; it does not prove suitability for an older person or generate an individual plan from urinary frequency, age or milligrams.
Read source: United States ↗reviewed 2026-08-29More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- DETROL LA
- Source-scoped market brand names
- DETROL LA · United StatesSource-scoped evidence ↗NDA 021228; 2 mg and 4 mg are current Orange Book prescription RLD products, with 4 mg also the RS; both displayed 30-capsule NDCs have a marketing end date of 31 Jul 2026.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- tolterodine tartrate extended-release capsules
- Dosage-form class
- Tolterodine tartrate extended-release oral capsules: 2 mg or 4 mg per capsule; the label says to swallow whole with liquid; not an immediate-release tolterodine tablet, fesoterodine extended-release tablet or another bladder medicine
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
2 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v4 (published 9 Jun 2025; prescribing information revised Mar 2023; this NDC marketing end date 31 Jul 2026)
Tolterodine tartrate 2 mg per capsule; 30-capsule bottle; this package record has a marketing end date of 31 Jul 2026
- Product code
- NDC 58151-103-93
- Form and route
- DETROL LA tolterodine tartrate extended-release oral capsule · oral (intact extended-release capsule identity field)
- Container
- 30-capsule prescription bottle label panel
- Listing review
- Cited product evidence reviewed 2026-08-29; actual marketing, stock and availability are not established.
- tolterodine tartrate
- 2 mglabelled amount per capsule; not an individual's capsule count, frequency, adjustment or switching instruction
- Package
- 30 capsules per bottle
- Labelled appearance
- blue-green with a white numeral 2 · capsule, approximately 14 mm; unscored; label says to swallow whole · imprint 2Unscored; the cited label says to swallow it whole
United States label · DailyMed SPL v4 (published 9 Jun 2025; prescribing information revised Mar 2023; this NDC marketing end date 31 Jul 2026)
Tolterodine tartrate 4 mg per capsule; 30-capsule bottle; this package record has a marketing end date of 31 Jul 2026
- Product code
- NDC 58151-104-93
- Form and route
- DETROL LA tolterodine tartrate extended-release oral capsule · oral (intact extended-release capsule identity field)
- Container
- 30-capsule prescription bottle label panel
- Listing review
- Cited product evidence reviewed 2026-08-29; actual marketing, stock and availability are not established.
- tolterodine tartrate
- 4 mglabelled amount per capsule; not an individual's capsule count, frequency, adjustment or switching instruction
- Package
- 30 capsules per bottle
- Labelled appearance
- blue with a white numeral 4 · capsule, approximately 16 mm; unscored; label says to swallow whole · imprint 4Unscored; the cited label says to swallow it whole
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
DETROL LA label reading: swallow the capsule whole and review anticholinergic burden with the complete medicine list
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The label says to swallow the capsule whole with liquid and tell the doctor if the capsule cannot be swallowed. The site does not turn 2 mg and 4 mg into an individual choice or interpret ‘extended-release capsule’ as permission to open, divide, crush or replace it with an immediate-release tablet.
- 2 mg and 4 mg are labelled amounts per capsule, while 30 is the bottle count. Although two 2 mg numbers add to 4 mg, that does not permit self-assembling capsules, changing an amount, replacing a 4 mg product, making up a dose or copying another person's prescription.
- Swallow the capsule whole with liquid. The label does not turn capsule appearance, lack of a score or ‘extended release’ into permission to open, chew, crush, divide or sprinkle it. For swallowing difficulty, take the exact pack and prescription to a pharmacist or prescriber for an appropriate plan.
- Dry mouth, constipation, abdominal pain, blurred vision, dizziness or drowsiness are important label adverse-effect cues. Older adults, people with cognitive impairment or fall risk, and those using sleeping, allergy, nausea, bladder or other anticholinergic medicines need priority review of the complete medicine list.
- Urinary retention, gastric retention and uncontrolled narrow-angle glaucoma are labelled contraindications. Gastrointestinal obstruction or reduced motility, myasthenia gravis, liver or kidney impairment and a history of QT prolongation also need to be disclosed.
- Swelling of the face, lips, tongue or throat, breathing difficulty, upper-airway obstruction or a fall in blood pressure needs emergency help. Severe distension, inability to pass stool or gas, inability to urinate, fainting or marked mental-status change also needs prompt medical assessment.
- Potent CYP3A4 inhibitors, other anticholinergics and some QT-related medicines may change risk. Label examples include clarithromycin, ritonavir, ketoconazole and certain antiarrhythmics; the site does not generate an individual reduction or time-separation schedule from this information.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-29
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 3
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): U.S. DETROL LA tolterodine tartrate extended-release capsule brand label (SPL v4; published 9 Jun 2025; prescribing information revised Mar 2023) ↗reviewed 2026-08-29
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-29FDA Drugs@FDA: current DETROL LA NDA 021228 application, RLD and RS record ↗reviewed 2026-08-29
- FDA · United States · Regulatory product record or label archive · 2026-08-29FDA: dated DETROL LA tolterodine tartrate extended-release capsule prescribing information (2018) ↗reviewed 2026-08-29
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about DETROL LA (tolterodine tartrate extended-release capsules). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
DETROL LA is the brand in this record and tolterodine tartrate extended-release capsules is the active-ingredient name. Check both with the dosage form (Tolterodine tartrate extended-release oral capsules: 2 mg or 4 mg per capsule; the label says to swallow whole with liquid; not an immediate-release tolterodine tablet, fesoterodine extended-release tablet or another bladder medicine) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): U.S. DETROL LA tolterodine tartrate extended-release capsule brand label (SPL v4; published 9 Jun 2025; prescribing information revised Mar 2023) ↗reviewed 2026-08-29
- FDA Drugs@FDA: current DETROL LA NDA 021228 application, RLD and RS record ↗reviewed 2026-08-29
- FDA: dated DETROL LA tolterodine tartrate extended-release capsule prescribing information (2018) ↗reviewed 2026-08-29
HOW IT WORKS · NOT A TREATMENT PLAN
How DETROL LA works: antimuscarinic action and an extended-release capsule are two different concepts
- The same pathway can also affect saliva, bowel, eyes, urination and the central nervous system, so a ‘bladder medicine’ label must not hide constipation, blurred vision, drowsiness, mental-status change or the complete medicine list.
- DETROL LA, DITROPAN XL, VESIcare, TOVIAZ and MYRBETRIQ are different products. A shared use does not make their ingredients, receptor actions, release designs, interactions or adverse effects the same, and does not permit self-combination, alternation or substitution by milligrams.
- Whole-genome screening is not a universal prerequisite set by this site for this choice. Review more directly requires the exact diagnosis and goals, cognition and fall risk, urinary and bowel status, glaucoma and rhythm history, liver and kidney function, and all medicines.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): U.S. DETROL LA tolterodine tartrate extended-release capsule brand label (SPL v4; published 9 Jun 2025; prescribing information revised Mar 2023) ↗reviewed 2026-08-29
- FDA Drugs@FDA: current DETROL LA NDA 021228 application, RLD and RS record ↗reviewed 2026-08-29
- FDA: dated DETROL LA tolterodine tartrate extended-release capsule prescribing information (2018) ↗reviewed 2026-08-29
- FDA: DETROL LA NDA 021228 original approval label (2000) ↗reviewed 2026-08-29
SOURCE-TRACEABLE ARCHIVE
DETROL LAtolterodine tartrate extended-release capsules
This page links to public primary-source material for DETROL LA. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
FDA initially approved DETROL LA 2 mg and 4 mg
The FDA original label and current Orange Book link both extended-release capsule strengths to NDA 021228.
FDA: DETROL LA NDA 021228 original approval label (2000) ↗Cited DailyMed prescribing-information revision
The label supports whole-capsule, anticholinergic CNS, urinary-retention, gastrointestinal, glaucoma, QT and interaction reading boundaries.
DailyMed (NLM): U.S. DETROL LA tolterodine tartrate extended-release capsule brand label (SPL v4; published 9 Jun 2025; prescribing information revised Mar 2023) ↗DailyMed SPL v4 published
This version provides exact 2 mg and 4 mg 30-capsule bottle panels and NDCs, while retaining their package marketing end dates.
DailyMed (NLM): U.S. DETROL LA tolterodine tartrate extended-release capsule brand label (SPL v4; published 9 Jun 2025; prescribing information revised Mar 2023) ↗Current U.S. Orange Book identity reviewed
Both 2 mg and 4 mg are listed as prescription RLD products, with 4 mg also the RS. This review does not establish current pharmacy stock.
FDA Drugs@FDA: current DETROL LA NDA 021228 application, RLD and RS record ↗
MARKET SCOPE
Market-record boundary
United States
Current Orange Book RLD identity; both displayed package NDCs are past their marketing end dateExact images remain useful for checking the dated brand, generic name, per-capsule strength, NDC and pack count; they do not establish current supply, purchase eligibility, authenticity or individual suitability.
Mainland China, EU, Japan and other markets
Current market records not establishedNo local brand, approval, pack, supply or interchangeability is inferred from the U.S. brand, NDA, RLD identity, generic name, milligrams or package colour.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Can a 4 mg capsule be opened and half used as 2 mg?
Do not do this yourself. The label says to swallow the capsule whole with liquid; the extended-release contents and their appearance are not a visual half-measure. Any adjustment requires review of the exact prescription, available product and swallowing concern.
Can it be taken with DITROPAN XL, VESIcare or MYRBETRIQ?
The site cannot decide from brand names alone. Ingredients, actions and risk boundaries differ; duplicate anticholinergic effects, urinary retention, constipation, dizziness, drowsiness, cognition and fall risk require professional review of the complete medicine list, diagnosis and individual context.
Does a package image mean it is currently available in the United States?
No. The images correspond to two dated 30-capsule NDCs whose DailyMed marketing end date is 31 Jul 2026. Orange Book RLD/RS identity, a label archive, real-time stock and purchasing eligibility are different evidence layers.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.